Selection of optimal therapeutic modality for early-stage extranodal natural killer/T-cell lymphoma patients under the guidance of single-nucleotide polymorphism signature

Bosn J Basic Med Sci. 2021 Aug 24. doi: 10.17305/bjbms.2021.6419. Online ahead of print.
No abstract available

Publication types

  • Letter
  • Comment